Plain-English translation of NCT07343193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is learning how to safely reduce or stop antipsychotic medications in people who have been on them long-term and are doing well. Doctors and patients often disagree about when it's safe to lower doses — doctors worry about relapse, while patients often want to stop because of side effects. This research will document real-life cases to help future patients and doctors make better decisions.
There is no clear agreement on the best way to reduce antipsychotic medications, including who should try it, when to start, how quickly to taper, and what to do if symptoms return. This study exists to learn from real-world experiences and create practical guidance for both patients and doctors.
You likely qualify if…
You likely don't qualify if…
This is an observational study, meaning researchers will follow and document your experience as you reduce your antipsychotic medication under your doctor's supervision — you are not being assigned to a specific treatment plan by the study. The researchers will collect information about your progress, any challenges you face, and whether your symptoms stay stable or change. The goal is to create real-world case studies that help other patients and doctors understand what to expect when tapering antipsychotics.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France
Enrollment target
~30 participants
Started
September 2025
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Fabrice BERNA, MD, PhD
University Hospital, Strasbourg, France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.